Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

BACKGROUND: Cisplatin-based chemotherapy was previously considered as the standard adjuvant therapy for improved overall survival (OS) in patients with non-small cell lung cancer (NSCLC) after surgery. However, the benefit was limited due to high risks of recurrence and adverse events. In the presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rui-Lian, Sun, Ling-Ling, Cao, Yang, Chen, Han-Rui, Zhou, Jing-Xu, Gu, Chu-Ying, Zhang, Ying, Wang, Si-Yu, Hou, Wei, Lin, Li-Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071858/
https://www.ncbi.nlm.nih.gov/pubmed/33912453
http://dx.doi.org/10.3389/fonc.2021.629394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071858/
https://www.ncbi.nlm.nih.gov/pubmed/33912453
http://dx.doi.org/10.3389/fonc.2021.629394

Ejemplares similares